Physician profile
Eunice Rhee
NPI 1306885009
$3,502.14
in general payments reported to CMS, 2019-2025
25 companies · $770 in 2025
The $770 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $403 · 2021: $529 · 2022: $276 · 2023: $343 · 2024: $730 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818 · Education: $24.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.93 |
| Education | $24.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $439.24 | 2020-2024 | Xifaxan, Trulance |
| Abbvie INC. | $438.38 | 2019-2023 | |
| Madrigal Pharmaceuticals | $413.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $237.18 | 2019-2025 | Sucraid |
| Axonics, INC. | $203.97 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.53 | 2019-2025 | Eohilia, Entyvio |
| Braintree Laboratories, INC. | $194.85 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $189.05 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $180.71 | 2024-2025 | Ibsrela |
| Boston Scientific Corporation | $157.50 | 2023-2025 | Axonics, Wavewriter Alpha Prime 16, Overstitch Endoscopic Suturing System |
| Lilly USA, LLC | $127.17 | 2023-2024 | Omvoh |
| Endogastric Solutions, INC | $125.69 | 2022 | |
| Alfasigma USA, INC. | $104.60 | 2020-2022 | |
| Celltrion USA INC. | $90.63 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $87.81 | 2019-2025 | Rebyota |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $57.31 | 2020-2024 | Talicia |
| Phathom Pharmaceuticals, INC. | $56.50 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $44.88 | 2024 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $31.16 | 2022 | |
| Exact Sciences Corporation | $30.60 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $21.13 | 2020 | |
| Shionogi INC | $20.19 | 2019 | |
| Gilead Sciences, INC. | $20.11 | 2020 | |
| Evoke Pharma, INC. | $15.63 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $13.33 | 2023 | Kristalose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eunice Rhee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.